BR112014012167A2 - métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina - Google Patents

métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina

Info

Publication number
BR112014012167A2
BR112014012167A2 BR112014012167A BR112014012167A BR112014012167A2 BR 112014012167 A2 BR112014012167 A2 BR 112014012167A2 BR 112014012167 A BR112014012167 A BR 112014012167A BR 112014012167 A BR112014012167 A BR 112014012167A BR 112014012167 A2 BR112014012167 A2 BR 112014012167A2
Authority
BR
Brazil
Prior art keywords
methods
cysteamine
derivative
adiponectin levels
treating
Prior art date
Application number
BR112014012167A
Other languages
English (en)
Inventor
Dohil Ranjan
A Phillips Susan
Original Assignee
The Regents Of The Univ Of Calefornia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The Univ Of Calefornia filed Critical The Regents Of The Univ Of Calefornia
Publication of BR112014012167A2 publication Critical patent/BR112014012167A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014012167A 2011-11-22 2012-11-21 métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina BR112014012167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563034P 2011-11-22 2011-11-22
PCT/US2012/066288 WO2013078335A1 (en) 2011-11-22 2012-11-21 Cysteamine and/or cystamine for treating ischemic injury

Publications (1)

Publication Number Publication Date
BR112014012167A2 true BR112014012167A2 (pt) 2017-05-30

Family

ID=47297472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012167A BR112014012167A2 (pt) 2011-11-22 2012-11-21 métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina

Country Status (16)

Country Link
US (1) US20140322315A1 (pt)
EP (1) EP2782564B1 (pt)
JP (1) JP6411215B2 (pt)
KR (1) KR20140097132A (pt)
CN (2) CN108042517A (pt)
AU (1) AU2012340670B2 (pt)
BR (1) BR112014012167A2 (pt)
CA (1) CA2851387A1 (pt)
HK (1) HK1202440A1 (pt)
IL (1) IL232608A0 (pt)
MX (1) MX2014004469A (pt)
MY (1) MY165953A (pt)
RU (1) RU2638807C2 (pt)
SG (2) SG10201800159QA (pt)
WO (1) WO2013078335A1 (pt)
ZA (1) ZA201402290B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
MX2018000202A (es) 2015-07-02 2018-06-27 Horizon Orphan Llc Analogos de cisteamina resistentes a la ado y sus usos.
CN106591461A (zh) * 2016-12-29 2017-04-26 天津协和华美医学诊断技术有限公司 一种检测遗传性易栓症相关基因群的检测试剂盒
US11020354B2 (en) 2017-01-19 2021-06-01 Otologic Pharmaceuticals, Inc. Formulations of n-acetylcysteine and uses thereof
MX2019008847A (es) * 2017-01-25 2019-12-16 Adare Pharmaceuticals Inc Profarmacos de cisteamina.
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
FR2573077B1 (fr) * 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
EP0306937A3 (en) * 1987-09-08 1990-07-25 The Green Cross Corporation Platelet agglutination-inhibiting agent
JPH02243619A (ja) * 1989-03-15 1990-09-27 Green Cross Corp:The 抗血小板凝集剤
WO1990014087A1 (en) 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (pt) 1993-09-02 1996-07-21 Hoffmann La Roche
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
BR9814867A (pt) 1997-10-24 2000-10-03 Warner Lambert Co Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
AU1808100A (en) 1998-10-28 2000-05-15 Vitaly V. Romanenko Electrodynamic particle size analyzer
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
JP4845740B2 (ja) * 2003-12-19 2011-12-28 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 糖尿病を治療するための組成物および方法
CA2565250C (en) * 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
KR20100091219A (ko) * 2007-11-30 2010-08-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 시스테아민 산물을 이용한 비-알코올성 지방성간염(ｎａｓｈ) 치료 방법
RU2428192C1 (ru) * 2010-06-10 2011-09-10 Войсковая Часть 41598 Радиозащитное средство

Also Published As

Publication number Publication date
ZA201402290B (en) 2017-06-28
SG11201402472QA (en) 2014-06-27
KR20140097132A (ko) 2014-08-06
MY165953A (en) 2018-05-18
MX2014004469A (es) 2014-08-01
SG10201800159QA (en) 2018-02-27
CN103974698A (zh) 2014-08-06
WO2013078335A1 (en) 2013-05-30
JP6411215B2 (ja) 2018-10-24
AU2012340670A1 (en) 2014-04-17
CN108042517A (zh) 2018-05-18
HK1202440A1 (en) 2015-10-02
EP2782564B1 (en) 2019-01-09
IL232608A0 (en) 2014-06-30
RU2638807C2 (ru) 2017-12-15
EP2782564A1 (en) 2014-10-01
AU2012340670B2 (en) 2016-12-22
JP2014533701A (ja) 2014-12-15
RU2014125282A (ru) 2015-12-27
US20140322315A1 (en) 2014-10-30
CA2851387A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
BR112014012167A2 (pt) métodos para tratar um indivíduo, um evento isquêmico, métodos para aumentar a razão de níveis de adiponectina e os níveis de adiponectina, e, cisteamina, derivado de cisteamina, derivado de cistamina
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BR112016014014A2 (pt) composição, método para a produção de um composto e método para o tratamento de um material
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BRPI0923756A2 (pt) método para produção de um componente de um dispositivo, e os componentes e dispositivos resultantes
BR112013018679A2 (pt) agente para o tratamento da alopecia
BR112014026974A2 (pt) camada de efeito óptico, dispositivo e método para produzir a mesma, documento de segurança e uso de uma camada de sefeito óptico
BR112014007649A2 (pt) material estruturante, e, método para o tratamento de uma formação subterrânea
CL2015002754A1 (es) Método para descelularización de injertos de tejido
BR112014015562A2 (pt) aerofólio e método para fabricar um aerofólio
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112016008939A2 (pt) Método para o tratamento de lignina e para a produção de uma composição ligante
BR112015027861A2 (pt) Dispensador de aplicação para pelo menos um componente
BR112013029507A2 (pt) método para tratar uma doença ou um distúrbio
BR112014030044A2 (pt) uma composição na forma de uma dispersão compreendendo uma lignina , um método para a manufaturação da mesma e utilização da mesma
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
BR112014013340A2 (pt) método para o processamento e cinzas, particularmente cinzas volantes
CO6970598A2 (es) Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.